Stereotactic body radiotherapy for oligo-recurrence in the liver in a patient with esophageal carcinoma: A case report.

Authors:
Atsuto Katano
Atsuto Katano
University of Tokyo Hospital
Bunky┼Ź | Japan
Hideomi Yamashita
Hideomi Yamashita
University of Tokyo Hospital
Japan
Keiichi Nakagawa
Keiichi Nakagawa
University of Tokyo Hospital
Japan

Mol Clin Oncol 2017 Dec 4;7(6):1061-1063. Epub 2017 Oct 4.

Department of Radiology, The University of Tokyo Hospital, Tokyo 113-8655, Japan.

Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for solitary cancerous lesions. The present study reported a rare case of sustained remission after SBRT for oligorecurrence in the liver in a patient with esophageal carcinoma. A 60-year-old Japanese man presented with a chief complaint of dysphagia. On medical examination, the patient was diagnosed as having squamous cell carcinoma of the esophagus that was clinically staged as T4bN1M0. The patient received definitive concurrent chemoradiotherapy, consisting of four 28-day cycles of chemotherapy comprising nedaplatin 80 mg/m on day 1 and S-1 120 mg/body orally on days 1-14, with radiotherapy comprising a total of 50 Gy in daily fractions of 2 Gy. After a 9-month disease-free interval following the primary treatment, a solitary liver metastasis was identified. The patient underwent SBRT using a radiation dose of 48 Gy in 4 fractions and two 28-day cycles of adjuvant chemotherapy comprising nedaplatin 80 mg/m on day 1, and S-1 100 mg/body orally on days 1-14. The patient exhibited no signs of recurrence for 3 years with sustained local control. SBRT may be considered a treatment option for patients with relapsed esophageal cancer with oligo-recurrence in the liver.

Download full-text PDF

Source
http://dx.doi.org/10.3892/mco.2017.1441DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740860PMC
December 2017
6 Reads

Publication Analysis

Top Keywords

esophageal carcinoma
8
day s-1
8
mg/m day
8
treatment solitary
8
mg/body orally
8
days 1-14
8
orally days
8
liver patient
8
patient esophageal
8
chemotherapy comprising
8
stereotactic body
8
28-day cycles
8
comprising nedaplatin
8
oligo-recurrence liver
8
nedaplatin mg/m
8
patient
6
s-1 100
4
received definitive
4
adjuvant chemotherapy
4
patient received
4

Similar Publications

Combined chemotherapy plus endostar with sequential stereotactic radiotherapy as salvage treatment for recurrent esophageal cancer with severe dyspnea: A case report and review of the literature.

Oncol Lett 2014 Jul 25;8(1):291-294. Epub 2014 Apr 25.

Cancer Center, Daping Hospital, Third Military Medical University, Chongqing 400042, P.R. China.

For the majority of inoperable esophageal cancer cases, chemoradiotherapy is the most suitable treatment option. Cetuximab may provide certain benefits, however, this can be an expensive therapy. Additionally, stereotactic body radiation therapy (SBRT) is typically contraindicated for esophageal cancer due to the potential for esophageal perforation and stenosis. Read More

View Article
July 2014

[A case of liver metastasis from esophageal cancer treated with stereotactic body radiation therapy].

Gan To Kagaku Ryoho 2013 Nov;40(12):1850-2

Dept. of Digestive Surgery, Saiseikai Yokohamashi Tobu Hospital.

A 70-year-old woman was diagnosed as having advanced lower thoracic esophageal cancer with abdominal lymph node metastases(T3N1M0, Stage III). After administering 2 courses of neoadjuvant chemotherapy with 5-fluorouracil(5- FU)( 800 mg/m2)and cisplatin(80 mg/m2), we performed curative surgery with D2 lymph node dissection. The patient could not receive adjuvant chemotherapy because of her poor performance status. Read More

View Article
November 2013

Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions.

J Gastrointest Oncol 2013 Dec;4(4):343-51

Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA;

Limited treatment options exist for isolated local recurrence of pancreatic ductal adenocarcinoma (PDA) following surgical resection accompanied by neoadjuvant or adjuvant chemoradiation therapy (CRT). While select patients are eligible for re-resection, recurrent lesions are often unresectable. Stereotactic body radiation therapy (SBRT) represents a possible minimally invasive treatment option for these patients, although published data in this setting are currently lacking. Read More

View Article
December 2013

Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study.

J Radiat Res 2016 Jan 22;57(1):55-61. Epub 2015 Oct 22.

Department of Radiology and Radiation Oncology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan

The purpose of this study was to investigate clinical outcomes following stereotactic body radiotherapy (SBRT) for lung metastases as oligo-recurrence. From May 2003 to June 2014, records for 66 patients with 76 oligo-recurrences in the lungs treated with SBRT were retrospectively reviewed. Oligo-recurrence primary sites and patient numbers were as follows: lungs, 31; colorectal, 13; head and neck, 10; esophagus, 3; uterus, 3; and others, 6. Read More

View Article
January 2016